产品
编 号：F295173
分子式：C20H17FN6
分子量：360.39
分子式：C20H17FN6
分子量：360.39
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
结构图
CAS No: 256376-24-6
产品详情
生物活性：
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research.
体内研究：
BAY 41-2272 (0.3-3 mg/kg；口服 单剂量；监测12 h) 对高血压犬有抑制作用。Animal Model:Hypertensive beagle dogs
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg
Administration:Oral gavage; single dose; monitored for 12 hr
Result:Decreased the mean BP (MBP) in a dose-dependent manner with a decrease of ?0.29?±?5.40?mmHg (p?=?0.7960) at the lowest dose of 0.3?mg/kg, ?5.51?±?11.45?mmHg (p?=?0.1625) after 1.0?mg/kg and ?14.05?±?1.81?mmHg (p?=?0.0042) after 3.0?mg/kg.
体外研究：
BAY 41-2272 (10 μM；15 分钟) 通过自身提高 cGMP 水平，并与 A7r5 大鼠主动脉平滑肌细胞中的 NO 供体 SNP (100 μM) 协同作用。
BAY 41-2272 is an orally active and soluble guanylate cyclases (sGC) activator, which increases sGC activity by 400-fold in synergy with NO. BAY 41-2272 potently unloaded the heart, increased cardiac output, thus can be used for cardiovascular diseases research.
体内研究：
BAY 41-2272 (0.3-3 mg/kg；口服 单剂量；监测12 h) 对高血压犬有抑制作用。Animal Model:Hypertensive beagle dogs
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg
Administration:Oral gavage; single dose; monitored for 12 hr
Result:Decreased the mean BP (MBP) in a dose-dependent manner with a decrease of ?0.29?±?5.40?mmHg (p?=?0.7960) at the lowest dose of 0.3?mg/kg, ?5.51?±?11.45?mmHg (p?=?0.1625) after 1.0?mg/kg and ?14.05?±?1.81?mmHg (p?=?0.0042) after 3.0?mg/kg.
体外研究：
BAY 41-2272 (10 μM；15 分钟) 通过自身提高 cGMP 水平，并与 A7r5 大鼠主动脉平滑肌细胞中的 NO 供体 SNP (100 μM) 协同作用。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备